Rebiotix to Present at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference
Download this press release (160 KB).
ROSEVILLE, MN (August 23, 2017) — Rebiotix Inc., a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to treat challenging diseases, announced today that it will present at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference, to be held September 8, 2017 at the Millennium Broadway Hotel & Conference Center in New York City.
Lee Jones, co-founder, president and CEO, will present Rebiotix’s corporate growth strategy and discuss the company’s pioneering Microbiota Restoration TherapyTM (MRT) platform and rapidly advancing drug development pipeline, highlighted by RBX2660 and RBX7455. RBX2660 is currently being evaluated in an international Phase 3 clinical trial for the prevention of recurrent Clostridium difficile (C. diff.) infection, while RBX7455, a lyophilized, non-frozen, oral capsule formulation, is the subject of a Phase 1 clinical study for the prevention of recurrent C. diff. infection.